Bayer to build first North American pharma plant in Ohio, adding 600 jobs
Bayer announced Friday, Oct. 2, 2026, a $2.2 billion pharmaceutical manufacturing campus in New Albany, Ohio, its first such North American operation. The New Albany International Business Park project is expected to create about 600 permanent jobs and 1,500 construction jobs. Drug-substance manufacturing is expected operational in 2031 and a drug-product module in 2034. The modular campus will use digital and automation technologies, initially support oncology, cardiovascular and renal care, and build on more than $7 billion in U.S. pharma R&D and manufacturing investment over five years. It joins existing U.S. sites including Whippany, N.J., and Berkeley, Calif. Bill Anderson, Bayer CEO, said the United States is a key manufacturing base and innovation hub and the investment underscores commitment to deliver medicines to patients in the U.S. and abroad. Sebastian Guth said the U.S. is Bayer's largest and fastest-growing market. Holger Weintritt called the site a strategic addition for supply resilience. Stefan Oelrich had earlier told The Wall Street Journal Bayer was looking to expand its U.S. manufacturing footprint. CONTESTED: Bloomberg framed the $2.2 billion plan against a tariff backdrop. Bayer describes it as long-term strategy to expand U.S. presence and strengthen medicine supply, not a response to a single policy change.
Where do you stand?




